Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Distinct effects on cAMP signaling of carbamazepine and its structural derivatives do not correlate with their clinical efficacy in epilepsy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Extensive astrocyte metabolism of γ-aminobutyric acid (GABA) sustains glutamine synthesis in the mammalian cerebral cortex

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identification of epilepsy-associated neuronal subtypes and gene expression underlying epileptogenesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Aspects of cAMP Signaling in Epileptogenesis and Seizures and Its Potential as Drug Target

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Genterapi til sygdomme i centralnervesystemet

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sara Krarup
  • Christoffer Mertz
  • Emil Jakobsen
  • Sandy E H Lindholm
  • Lars H Pinborg
  • Lasse K Bak
Vis graf over relationer

The antiepileptic sodium channel blocker, carbamazepine, has long been known to be able to attenuate cAMP signals. This could be of clinical importance since cAMP signaling has been shown to be involved in epileptogenesis and seizures. However, no information on the ability to affect cAMP signaling is available for the marketed structural derivatives, oxcarbazepine and eslicarbazepine acetate or their dominating metabolite, licarbazepine. Thus, we employed a HEK293 cell line stably expressing a cAMP biosensor to assess the effect of these two drugs on cAMP accumulation. We find that oxcarbazepine does not affect cAMP accumulation whereas eslicarbazepine acetate, surprisingly, is able to enhance cAMP accumulation. Since the transcription of ADCY8 (adenylyl cyclase isoform 8; AC8) has been found to be elevated in epileptic tissue from patients, we subsequently expressed AC8 in the HEK293 cells. In the AC8-expressing cells, oxcarbazepine was now able to attenuate whereas eslicarbazepine maintained its ability to increase cAMP accumulation. However, at all concentrations tested, licarbazepine demonstrated no effect on cAMP accumulation. Thus, we conclude that the effects exerted by carbamazepine and its derivatives on cAMP accumulation do not correlate with their clinical efficacy in epilepsy. However, this does not disqualify cAMP signaling per se as a potential disease-modifying drug target for epilepsy since more potent and selective inhibitors may be of therapeutic value.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Pharmacology
Vol/bind886
Sider (fra-til)173413
ISSN0014-2999
DOI
StatusUdgivet - 5 nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 61289882